Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the long-term safety and tolerability of
renzapride at a dose of 4 mg taken once daily for 12 months in women with
constipation-predominant irritable bowel syndrome (IBS-C).